SCHEMBL2661410

SCHEMBL2661410

Cc1nn(C)cc1-c1cccc2c(N)c3c(nc12)CN(C1CCC1)C3=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.37
▸ RGS12 O14924 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ACVR1 Q04771 5/20 0.35
▸ BMPR1A P36894 4/20 0.35
▸ ACVRL1 P37023 4/20 0.35
▸ BRD4 O60885 4/20 0.33
▸ CREBBP Q92793 4/20 0.33
▸ POLB P06746 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ FGFR1 P11362 1/20 0.32
▸ FGFR4 P22455 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ TMEM97 Q5BJF2 1/20 0.32
▸ HTR3A P46098 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661459 0.84 ACVR1 (0.48) ACVR1BMPR1AACVRL1BRD4PIK3CG
SCHEMBL4923597 0.83 MAPK1 (0.35) MEN1KMT2AACVR1BMPR1AACVRL1
SCHEMBL2669426 0.83 NPY1R (0.40) MEN1MAPTKMT2APOLBHTR2B
SCHEMBL2669534 0.82 LCK (0.46) ACVR1BMPR1AACVRL1
SCHEMBL2669400 0.81 PIK3CA (0.35) ACVR1BMPR1AACVRL1POLBPARP1
SCHEMBL2660877 0.81 MAPK1 (0.43) MAPTPOLBPARP1HTTESR2
SCHEMBL2661112 0.81 BMPR1A (0.32) MEN1MAPTKMT2AACVR1BMPR1A
SCHEMBL2661491 0.81 MAPK1 (0.35) MEN1KMT2AACVR1BMPR1AACVRL1
SCHEMBL4916106 0.81 NPY1R (0.42) MAPTPOLBHTR2BHTR3A
SCHEMBL4924467 0.81 HRH4 (0.41) MEN1KMT2AACVR1BMPR1AACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF MEN1 1506/4885RGS12 1856/4885USP2 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback